Company Monitoring Page for Alnylam

latest headlines for company on cafepharma

FDA adds ‘breakthrough’ status for Alnylam as patisiran starts its victory lap at the agency
Endpoints
Mon, 11/20/17 - 07:45 pm
Tags:
FDA, Alnylam, Patisiran, breakthrough status
Alnylam Starts Rolling NDA Submission for RNAi Candidate
Yahoo/Zacks.com
Fri, 11/17/17 - 11:12 am
Tags:
Alnylam, RNAi, hereditary ATTR amyloidosis, FDA, Patisiran
Alnylam outshines Ionis with RNAi drug
BioPharma Dive
Sat, 11/4/17 - 08:40 am
Tags:
Alnylam, Ionis Pharmaceuticals, RNAi, Sanofi, Patisiran, amyloidosis
The Medicine Company's Dangerous Bet On Its LDL Cholesterol Lowering Drug
Forbes
Thu, 10/26/17 - 09:34 am
Tags:
The Medicine Company, LDL cholesterol, inclisiran, Alnylam, PCSK9 inhibitors
With $500M-plus, a buyout and two new billion-dollar pacts, upstart Vir is ready to roll on infectious diseases
Endpoints
Wed, 10/18/17 - 10:08 am
Tags:
Vir Biotechnology, George Scangos, Alnylam, Visterra
A drug 15 years in the making: Alnylam's quest to prove RNAi
BioPharma Dive
Sat, 09/30/17 - 10:16 am
Tags:
Alnylam, RNAi, Patisiran
3 Biotech Stocks That Skyrocketed Last Week: Can They Go Higher?
Motley Fool
Mon, 09/25/17 - 09:42 am
Tags:
Madrigal Pharmaceuticals, MGL-3196, Alnylam, Sanofi, Arbutus BioPharma
Alnylam’s rare disease drug shines in trial, paving way for a brand-new class of medicines
Stat
Wed, 09/20/17 - 09:27 am
Tags:
Alnylam, rare disease, Patisiran, familial amyloid polyneuropathy, RNAi
On Eve of Big Data Reveal, Patient Death Stalls Alnylam Hemophilia Drug
Xconomy
Thu, 09/7/17 - 05:46 pm
Tags:
Alnylam, fitusiran, hemophilia
3 Biotech Stocks That Could Soar in September
Motley Fool
Sun, 08/27/17 - 06:26 pm
Tags:
biotech, fitusiran, Alnylam, PTC Therapeutics, Translarna, Sarepta, Exondys 51
Alnylam review turns up no clear answers on revusiran deaths
BioPharma Dive
Thu, 08/10/17 - 06:53 pm
Tags:
Alnylam, revusiran, RNAi
3 Drug Stocks Poised to Surpass Estimates in Q2 Earnings
Yahoo/Zacks.com
Wed, 08/9/17 - 09:41 am
Tags:
earnings, Puma Biotechnology, Alnylam, Impax Labs
Sanofi and Alnylam plunge into PhIII with a rival to Roche’s top hemophilia drug
Endpoints
Fri, 07/7/17 - 10:22 am
Tags:
Sanofi, Alnylam, clinical trials, fitusiran, hemophilia, Roche, emicizumab
5 Biotech Stocks With Major Catalysts in July
Motley Fool
Wed, 06/28/17 - 11:03 pm
Tags:
biotech, AcelRx, Zalviso, Alnylam, Patisiran, Dynavax, HEPLISAV-B, GSK, Benlysta, Puma Biotechnology, neratinib
Alnylam lines up Phase 3 for another RNAi drug
BioPharma Dive
Tue, 06/27/17 - 10:33 am
Tags:
Alnylam, RNAi, givosiran, acute hepatic porphyrias
5 Best Biotech Stocks of 2017 So Far
Motley Fool
Mon, 06/26/17 - 09:41 am
Tags:
biotech, Alnylam, Puma Biotechnology, Immunogen, Sangamo BioSciences, Calitera
​Alnylam CEO’s pay fell nearly 80 percent in 2016
Bizjournals.com
Mon, 03/20/17 - 11:28 pm
Tags:
Alnylam, Pharma CEOs, John Maraganore, executive pay
7 of the Most Shocking Biotech Pipeline Blowups of 2016
Motley Fool
Sun, 12/4/16 - 12:37 pm
Tags:
biotech, Alnylam, revusiran, Clovis Oncology, rociletinib, Celldex Therapeutics, Rintega, Eli Lilly, solanezumab, Novavax, RSV-F, Arrowhead, ARC-520, ARC-521, ARC-AAT, Biomarin, drisapersen
Alnylam touts hemophilia drug's edge over Roche rival
BioPharma Dive
Fri, 12/2/16 - 10:48 am
Tags:
Alnylam, Roche, hemophilia, fitusiran
Alnylam Pharma stock plummets 45% after discontinuing drug on patient safety concerns
Marketwatch
Thu, 10/6/16 - 09:24 am
Tags:
Alnylam, clinical trials, revusiran

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.